Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Germany
  4. Xetra
  5. Bayer AG
  6. Summary
    BAYN   DE000BAY0017

BAYER AG

(BAYN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Xetra
09/13/2021 09/14/2021 09/15/2021 09/16/2021 09/17/2021 Date
45.925(c) 45.895(c) 45.41(c) 45.64(c) 45.21(c) Last
1 864 109 1 769 140 2 382 083 1 949 028 5 719 644 Volume
+0.33% -0.07% -1.06% +0.51% -0.94% Change
More quotes
Estimated financial data (e)
Sales 2021 42 596 M 49 939 M 49 939 M
Net income 2021 860 M 1 009 M 1 009 M
Net Debt 2021 39 369 M 46 156 M 46 156 M
P/E ratio 2021 31,9x
Yield 2021 4,51%
Sales 2022 43 923 M 51 496 M 51 496 M
Net income 2022 5 371 M 6 297 M 6 297 M
Net Debt 2022 38 034 M 44 591 M 44 591 M
P/E ratio 2022 9,86x
Yield 2022 4,83%
Capitalization 44 415 M 52 137 M 52 073 M
EV / Sales 2021 1,97x
EV / Sales 2022 1,88x
Nbr of Employees 99 439
Free-Float 100,0%
More Financials
Company
Bayer AG is a German-based life science company. The Company's segments are Pharmaceuticals, Consumer Health, Crop Science and Animal Health. The Pharmaceuticals segment focuses on researching, developing and marketing prescription products and specialty therapeutics especially in the areas of cardiology, oncology, gynecology, hematology and ophthalmology, as well as radiopharmacology and others. The company is... 
Sector
Pharmaceuticals
Calendar
11/09Earnings Release
More about the company
Ratings of Bayer AG
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about BAYER AG
07:04aBAYER AG : Morgan Stanley maintains a Buy rating
MD
09/16BWX TECHNOLOGIES : BWXT Medical to Collaborate With Bayer on Actinium-225 Radioi..
MT
09/16BAYER : launches transparency register for scientific collaborations with extern..
PU
09/16BAYER : Reports 'Sustained Clinical Benefit' From New Studies on Vitrakvi Cancer..
MT
09/16BAYER : Latest analyses of Vitrakvi (larotrectinib) reaffirm powerful efficacy a..
PU
09/15BAYER AG : Credit Suisse sticks Neutral
MD
09/15PRESS RELEASE : Tele Columbus AG: Eisenbahner-Wohnungsbaugenossenschaft (EWG) an..
DJ
09/15Deutsche Bank Eyes External Candidates for Chairman
MT
09/14BAYER : Unit Co-Leads $15 Million Funding Round for US-Based Biotechnology Group
MT
09/14BAYER : Andes Raises USD 15 Million in Series A Funding Co-Led by Leaps by Bayer..
BU
09/13BAYER AKTIENGESELLSCHAFT : Release -2-
DJ
09/13BAYER AKTIENGESELLSCHAFT : Release according to Article 40, Section 1 of the WpH..
DJ
09/09VC DAILY : Digital Health Is Booming, but VC Doesn't See a Bubble Forming
DJ
09/09BAYER : To Release New Data On Cancer Treatments At ESMO Congress
MT
09/09BAYER : to highlight expanded research from growing oncology portfolio at ESMO C..
PU
More news
News in other languages on BAYER AG
09/16BAYER : lance un registre de transparence en Allemagne
09/16BAYER : l'efficacité du Vitrakvi confirmée par quatre études
09/16Bayer fait état d'un "bénéfice clinique durable" dans de nouvelles études sur..
09/16Bellingham fühlt sich 'wie beim Basketball' - Doch BVB hält stand
09/15La Deutsche Bank envisage des candidats externes pour le poste de président
More news
Analyst Recommendations on BAYER AG
More recommendations
Chart BAYER AG
Duration : Period :
Bayer AG Technical Analysis Chart | BAYN | DE000BAY0017 | MarketScreener
Technical analysis trends BAYER AG
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Last Close Price 45,21 €
Average target price 62,45 €
Spread / Average Target 38,1%
EPS Revisions
Managers and Directors
Werner Baumann Chairman-Management Board & CEO
Wolfgang U. Nickl Chief Financial Officer
Norbert Winkeljohann Chairman-Supervisory Board
Bijoy Sagar Chief Information Technology Officer
Paul Achleitner Member-Supervisory Board
Sector and Competitors
1st jan.Capi. (M$)
BAYER AG-5.22%52 750
JOHNSON & JOHNSON4.98%434 939
ROCHE HOLDING AG11.70%327 062
PFIZER, INC.19.23%249 329
NOVO NORDISK A/S51.34%233 887
ELI LILLY AND COMPANY36.28%209 456